Navigation Links
GLEEVEC - An Oral treatment for leukemia

The U.S.Food and Drug Administration (FDA) at a conference in Washington, approves the new leukemia drug-GLEEVEC, first of its kind that directly removes the sign of a protein known to cause cancer. It is given as an oral treatment for chronic myelogenous leukemia (CML). Other molecular-targeting drugs previously approved by the FDA interfere with proteins associated with other cancers, but not with proteins that directly cause the disease.

Gleevec, was discovered and developed by Novartis Oncology in collaboration with its colleagues. CML is a disease in which too many white blood cells are produced in the bone marrow. In the early stages of CML, most patients do not have any symptoms of cancer,but the disease progresses slowly.

In the chronic phase, bone marrow transplantation is the only known cure. But there are many problems and side effects regarding the tranplantation which makes it more difficult to perform.

Gleevec has produced higher remission rates in comparison to the drug-interferon alfa, in three short-duration, early phase clinical trials.After many clinical trials - the FDA approved Gleevec.

Richard Klausner, M.D., director of the National Cancer Institute, said that he shared in the excitement of people with CML, but he also mentioned several caveats. He said many research questions remain to be answered, such as how long Gleevec will control CML. Does the drug actually cure CML patients? Or, does it delay the onset of moreadvanced forms of the cancer?

According to Klausner, "Gleevec offers proof that molecular targeting works in treating cancer, provided that the target is correctly chosen. The challenge now is to find these targets."

Courtesy: Novartis Oncology
'"/>




Page: 1

Related medicine news :

1. GLEEVEC - An Oral treatment for leukemia
2. Thyroid hormone treatment hastens recovery after cardiac surgery
3. Feeding channel created by malaria parasite - a new target for malaria treatments
4. Now umbilical cord helps in stroke treatment.
5. Now AIDS treatment comes dirt-cheap
6. Breast cancer treatment to be determined by gene test
7. Hemopurifier may revolutionise AIDS treatment
8. New drug helps boost cancer treatment
9. Antidepressants come in handy for patients on treatment for hepatitis, cancers and multiple sclerosis
10. Experimental treatment for Ebola Virus Shows promising results in mice
11. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/25/2017)... ... September 25, 2017 , ... ... excited to announce the next generation for LASIK in Manhattan with Contoura Vision, ... most technologically advanced laser systems available in the United States to correct nearsightedness ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... Community”: a gripping look at the religious stand in the sensitive matter ... love and compassion. “The Ministry of Reconciliation: A Compassionate and Realistic Approach to ...
(Date:9/25/2017)... ... ... The trend-spotters, tastemakers, and healthy lifestyle product experts at the New ... with the new NEXTY Gold Award at the Natural Products Expo East trade show ... is reserved for just those companies that hit high marks on the criteria of ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... September 28, 2017 to deliver a powerful message of teamwork, unity and collaboration ... Feature film writer/director Robert Adetuyi (Beat the World, Stomp the Yard) and Grammy-nominated ...
(Date:9/24/2017)... Michigan (PRWEB) , ... September 23, 2017 , ... Throughout ... do no harm. , Every day, physicians, nurses and other providers work to ... treatments and innovative industry processes. , But U.S. Senators today are threatening to ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... ANN ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical ... the precise destruction of targeted tissues, announced three leadership team developments today:   ... Josh Stopek, PhD ... ... Veteran medical device executive ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 ... performance ratings for global supply chains, has published the first annual edition ... CSR performance of more than 20,400 companies evaluated by EcoVadis, based on ... 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
(Date:9/9/2017)... 9, 2017  Eli Lilly and Company (NYSE: ... endpoint data for lasmiditan, an investigational, oral, first-in-class molecule ... significant improvements compared to placebo in the Phase 3 ... the 18th Congress of the International Headache Society (IHC) ... data presented today demonstrate lasmiditan,s potential to reduce pain ...
Breaking Medicine Technology: